Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05142150

Palliation in Gynae-oncology: Patients Expectations and Assessment of Care (PEACE)

The overall aim is to assess the feasibility and acceptability of collecting data on the patients and carers perception of care as well as to prospectively monitor end of life care.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Gynaecological Cancer

Age range

18 year and older

Sex eligibility

Female

Study type

Observational

Primary location

The Norwegian Radium Hospital

Oslo, 0310, Norway

Location status: Recruiting

Location contact

Kristina Lindemann, MD, PhD

CONTACT

[email protected]

+47 22934000 ext. 5690

Kristina Lindemann, MD, PhD

PRINCIPAL_INVESTIGATOR

About this study

Prospective observational cohort study.

Little is known about end of life care (EOL) in patients with ovarian or other gynaecological cancers. Patients typically have a high symptom burden and following several prior lines of therapy or the development of platinum resistant disease response rates to further active treatment are limited. Eliciting patients' values and preferences for end-of-life care and shared decision-making are central elements of patient-centered EOL care. The aim of this study is to assess the feasibility of collecting data on patient satisfaction towards end of life. Preliminary data on patient and carer satisfaction with care, the importance of aspects of care, as well as end of life treatment will also be collected. The study will also assess the carer satisfaction with care during bereavement and with the patient's dying experience.

The study will recruit beyond the targeted number of 73 patients number if the study is progressing favourably. Ideally, each patient will nominate a carer to also complete questionnaires and the carer will be able to assist in completing the diary, although this is not mandatory.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

A patient will be eligible for inclusion only if all of the following criteria are fulfilled:

  • Patients with any advanced gynecological malignancy and a life expectancy of approximately 4 months as estimated by their treating physician*. Potential patient groups include, but are not limited to, those with platinum-resistant/refractory recurrent epithelial ovarian cancer (PRR-EOC), metastatic/recurrent cervical or endometrial cancer progressing after platinum-based chemotherapy; high grade/undifferentiated metastatic uterine sarcoma progressing after first-line chemotherapy etc.
  • Patients may be on active cancer treatment, about to commence active cancer treatment or under observation/palliative care.
  • Age ≥ 18 years
  • Able (both physically and cognitively) to complete patient-reported outcome measures independently in languages that are available in this study (i.e. without assistance from hospital translator).

Exclusion criteria

A patient will not be eligible for inclusion if any of the following criteria are fulfilled:

  • Unable to be comply with the protocol.
  • A medical or psychological condition that limits the patient´s capacity to give informed consent, such as cognitive impairment, delirium, psychosis etc.
  • Participation in another clinical trial.

A patient will be asked to appoint a carer.

Inclusion criteria

carer:

  • Age ≥ 18 years
  • A relative or close friend who is actively supporting the patient in her illness
  • Able (both physically and cognitively) to complete questionnaires independently in languages that are available in this study (i.e. without assistance from hospital translator).

Exclusion criteria

carer

A carer will not be eligible for inclusion if any of the following criteria are fulfilled:

  • Unable to be comply with the protocol
  • A medical or psychological condition that limits the carer´s capacity to give informed consent, such as cognitive impairment, delirium, psychosis etc.

Treatment and study plan

Questionaire

Other

Patient questionaires collecting data on quality of life, illness management, communication and decision making. Patient report data of end of life care ( i.e administration of chemotherapy, surgical interventions, palliative care involvement, hospital admissions) through as self reported diary.

Carer for patients questionnaires their satisfaction with care. 5-7 weeks after patient deceased carer completes bereavement questionnaire and quality of death and dying.

Primary outcomes

  1. Number of patients who complete scheduled assessments with Canadian Health Care Evaluation Project (CANHELP) instrument, CANHELP Lite Individualised version

    Time frame: Within 42 days before their death

    To study the feasibility of collecting data on patient satisfaction with care. In all CANHELP Lite versions response options for each item range from 1'not at all satisfied' to 5 'completely satisfied'. All versions have an overall satisfaction with care score, as well as scores on each of the individual domains. All scores are re-scaled to range between 0 (worst possible value) to 100 (best possible value).

Secondary outcomes

  1. Number of carers who complete scheduled assessments with Canadian Health Care Evaluation Project (CANHELP) Lite Individualized Caregiver

    Time frame: Within 42 days before patient's death

    To study the feasibility of collecting data on carer satisfaction with care. In all CANHELP Lite versions response options for each item range from 1'not at all satisfied' to 5 'completely satisfied'. All versions have an overall satisfaction with care score, as well as scores on each of the individual domains. All scores are re-scaled to range between 0 (worst possible value) to 100 (best possible value).

  2. Number of carers who complete scheduled assessments with Canadian Health Care Evaluation Project (CANHELP) Lite bereavement and Quality of Death and Dying (QODD) questionnaire

    Time frame: Within 42 days of death up to 5-7 weeks after patient deceased.

    To study the feasibility of collecting data on carer satisfaction with care leading up to the time of death and the quality of the patient´s death. CANHELP response options range from 1'not at all satisfied' to 5 'completely satisfied', with an overall satisfaction with care score and scores on each individual domains. All scores are re-scaled to range 0 (worst possible value) to 100 (best possible value). The QODD questionnaire has 24 items that assess aspects of dying and death. The QODD questionnaire contains 14 additional items that assess cargiver's demographic characteristics and relation to the deceased. Response options for each item are rated on a scale from 0 (terrible) to 10 (almost perfect). The items provide a single score, derived as a mean of the item values, transformed to a 0 to 100 scale.

  3. Number of patients who received chemotherapy and other interventions as well as palliative care

    Time frame: Within 42 days before their death

    To study use of chemotherapy, surgical interventions as well as palliative care involvement

  4. Patient satisfaction with care

    Time frame: Baseline up to 5-7 weeks after patient deceased

    Patient satisfaction will be assessed with CANHELP Lite Individualized. In all CANHELP Lite versions response options for each item range from 1'not at all satisfied' to 5 'completely satisfied' . A 'not applicable/not discussed' response option for items that patients/cares felt was not relevant to their situation. All versions have an overall satisfaction with care score, as well as scores on each of the individual domains. All scores are re-scaled to range between 0 (worst possible value) to 100 (best possible value). The questionnaires will be administered and scored in accordance with the user manual.

  5. Carers satisfaction with care

    Time frame: Baseline up to 5-7 weeks after patient deceased

    Satisfaction will be assessed with CANHELP Lite bereavement and quality of death and dying (QODD) questionnaire.

    The QODD questionnaire has 24 items that assess various aspects of dying and death including whether the patient's symptoms were adequately controlled, whether dignity was maintained, time spent with loved ones in days leading up to death and whether the patient's wishes were adhered to. The QODD questionnaire also contains 14 additional items that assess the cargiver's demographic characteristics and relation to the deceased. The response options for each item are rated on a scale from 0 (terrible) to 10 (almost perfect). The items provide a single score, derived as a mean of the item values, transformed to a 0 to 100 scale.

  6. The importance of aspects of care for patients

    Time frame: Baseline up to 5-7 weeks after patient deceased

    Importance of aspects of care will be assessed through CANHELP Lite.

  7. The importance of aspects of care for carers

    Time frame: Baseline up to 5-7 weeks after patient deceased

    Importance of aspects of care assessed through CANHELP Lite.

Study contacts

Contact information is provided by the study sponsor or research team.

Kristina Lindemann, MD, PhD

CONTACT

[email protected]

004722934983

Sanne Nygaard Lindberg, MSc

CONTACT

[email protected]

004535453398

Sponsors and collaborators

Lead sponsor

Nordic Society of Gynaecological Oncology - Clinical Trials Unit

Other

Collaborators

  • Australia New Zealand Gynaecological Oncology Group

Registry information

Official study title

Palliation in Gynae-oncology: Patients Expectations and Assessment of Care

Acronym: PEACE

Important dates

Study start
2023
Primary completion
2025
Study completion
2027
First posted
Dec 2, 2021
Registry last updated
Oct 1, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.